|Videos|October 19, 2021
Treatment Options for Bipolar Disorder
Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.
Advertisement
Episodes in this series
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
5